Communiqués Spruce Biosciences, Inc.

Actions

SPRB

US85209E2081

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 08/10/2026			Varia. 5j.	Varia. 1 janv.
45,54 ^USD	+2,57%		0,00%	-

18/09	Spruce Biosciences, Inc. : Lake Street maintient sa recommandation à l'achat	ZM
26/08	Spruce Biosciences lance MPS3BStudy.com et annonce un programme d'accès élargi pour le TA-ERT ainsi que l'étude de confirmation TrAnsform	CI

Communiqués

08/10	Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting	BU
08/09	Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference	BU
26/08	Spruce Biosciences Announces Launch of MPS3BStudy.com	BU
24/08	Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026	BU
13/08	Spruce Biosciences - Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences	AQ
12/08	Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates	BU
12/08	Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences	BU
03/08	Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development	BU
27/07	Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer	BU
29/06	Spruce Biosciences Joins the Russell 3000® Index	BU
22/06	Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs	BU
15/06	Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller	BU
08/06	Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium	BU
28/05	Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium	BU
27/05	Spruce Biosciences to Participate in Upcoming Conferences in June	BU
13/05	Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates	BU
04/05	Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations	BU
21/04	Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants	BU
20/04	Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	BU
09/03	Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates	BU
09/03	Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer	BU
02/03	Spruce Biosciences to Present at Upcoming Investor Conferences in March	BU
18/02	Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)	BU
17/02	Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference	BU
05/02	Spruce Biosciences : 22nd Annual WORLDSymposium Poster Muschol (February 5, 2026)	PU